Showing results (171-180 of 347) with videos related to
Sort By:
Pageof 35
Blood|August 2, 2018
Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in miceEmma C Fink, Marie McConkey, Dylan N Adams, et al.Blood Advances|January 4, 2018
Agonistic targeting of TLR1/TLR2 induces p38 MAPK-dependent apoptosis and NFκB-dependent differentiation of AML cellsMia Eriksson, Pablo Peña-Martínez, Ramprasad Ramakrishnan, et al.Science (New York, N.Y.)|December 3, 2013
Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cellsJan Krönke, Namrata D Udeshi, Anupama Narla, et al.American Journal of Hematology|December 6, 2019
Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapyJacqueline S Garcia, Shruti Bhatt, Geoffrey Fell, et al.Nature Chemical Biology|April 6, 2026
Charged molecular glue discovery enabled by targeted degron displayZhe Zhuang, Woong Sub Byun, Jakub Chrustowicz, et al.Nature Genetics|March 17, 2009
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasmsOuti Kilpivaara, Semanti Mukherjee, Alison M Schram, et al.Nature Medicine|October 19, 2021
Distinction of lymphoid and myeloid clonal hematopoiesisAbhishek Niroula, Aswin Sekar, Mark A Murakami, et al.EMBO Molecular Medicine|February 14, 2024
Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cellsJan Mueller, Roman R Schimmer, Christian Koch, et al.Blood|September 17, 2014
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patientsRafael Bejar, Allegra Lord, Kristen Stevenson, et al.Nature Medicine|March 19, 2013
Macrophages support pathological erythropoiesis in polycythemia vera and β-thalassemiaPedro Ramos, Carla Casu, Sara Gardenghi, et al.Pageof 35